Becton, Dickinson (BDX)

The sleeper story is that BD's vaccine business collapse signals a permanent shift in healthcare delivery that competitors haven't fully grasped yet, while their BD Excellence manufacturing advantage is creating a cash generation machine trading at 10x earnings. Management's honest admission that vaccine demand 'evolved rapidly' beyond their planning shows this isn't temporary cyclical weakness. The binding constraint isn't demand in their core 90% of business growing mid-single digits, it's commercial execution where they're finally investing $30M and created their first Chief Revenue Officer. Quote that matters: 'We don't see that as a profile of a 10x stock' while sitting on 25% operating margins and $4B of buyback firepower. My view changes if vaccine decline reverses by Q2 or if the $30M selling investment doesn't drive visible acceleration by Q3.